Drug Trial Radar · NCT07490327
Assessment of Dutasteride Topical Solution in Male Androgenetic Alopecia
Last checked: Nov 19, 2026Latest source record: Mar 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Apr 2026
Primary completion
Sep 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Moogene Medi Co., LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Seoul National University Hospital
- First posted
- Mar 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 19 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, open-label phase 1/2a study designed to evaluate the pharmacokinetics, pharmacodynamics, and safety of AD-303A (topical formulation) and AD-3031 in male patients with androgenetic alopecia. The study aims to compare pharmacological characteristics and safety profiles to support dose selection for further clinical development.
Conditions
- Androgenetic Alopecia
Interventions
AD-303ADrug
Topical AD-303A applied to the scalp according to the study protocol.
AD-3031Drug
Oral AD-3031 administered according to the study protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma concentration (Cmax) of dutasterideTime frame: Up to Day14
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Seoul National University Hospital
Seoul, Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.